시장보고서
상품코드
1673034

급성 신손상(AKI) 치료 시장 : 유형별, 치료별, 유통 채널별, 지역별

Acute Kidney Injury Treatment Market, By Type, By Treatment, By Distribution Channel, By Geography

발행일: | 리서치사: Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 급성 신손상(AKI) 치료 시장은 2025년 19억 6,000만 달러, 2032년에는 34억 3,000만 달러에 달할 것으로 예측되며, 2025-2032년간 연평균 8.3% 성장할 것으로 예상됩니다.

보고 범위 보고서 상세 내용
기준 연도 2024년 2025년 시장 규모 19억 6,000만 달러
실적 데이터 2020-2024년 예측 기간 2025-2032년
예측 기간(2025-2032년) CAGR 8.30% 2032년 금액 예측 34억 3,000만 달러
그림. 2025년 지역별 급성 신손상(AKI) 치료 시장 점유율(%)
Acute Kidney Injury Treatment Market-IMG1

급성신손상(AKI)은 신장의 급격한 기능 저하로 인해 정상적으로 신장에서 제거되어야 할 노폐물이 혈액에 축적되는 것을 말합니다. 더 이상의 신장 손상이나 신부전을 예방하기 위해 신속한 치료가 필요한 심각한 상태입니다. 세계 급성신손상 치료제 시장의 성장을 주도하는 것은 AKI의 위험을 높이는 당뇨병, 고혈압과 같은 동반질환의 유병률 증가입니다. 또한, 새로운 약물 및 치료 접근법의 개발로 인해 환자의 치료 옵션이 확대되고 있습니다. 그러나 AKI에 대한 환자 및 의료진의 인식 부족은 시장 성장을 저해하는 요인으로 작용할 수 있습니다.

시장 역학

세계 급성 신손상(AKI) 치료제 시장의 성장을 주도하고 있는 것은 노화에 따른 신장 기능 저하로 AKI에 취약한 노년층 증가입니다. UN에 따르면, 65세 이상 노인 인구는 2050년까지 15억 명 이상에 달할 것으로 예측되고 있습니다. 생활습관의 변화로 인한 만성 신장질환의 유병률 증가도 시장 성장의 원동력이 될 것입니다. 그러나 신장 대체 요법의 높은 비용은 보급을 제한할 수 있으며, AKI 조기 진단에 대한 인식 부족은 시장 성장을 저해할 수 있으며, AKI를 조기에 발견할 수 있는 바이오마커의 개발은 시장 개척 기업에게 이 부문에서 사업을 확장할 수 있는 기회로 작용할 수 있습니다. 체액 상태의 실시간 모니터링은 실시간 맞춤형 케어를 의미합니다. 디지털 헬스 솔루션은 원격 환자 관리에도 도움이 됩니다.

본 조사의 주요 특징

세계의 급성 신장애 치료제 시장을 상세하게 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 연평균 성장률(CAGR)을 조사하여 전해드립니다.

또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.

또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.

세계 급성 신손상(AKI) 치료제 시장의 주요 기업 프로파일을 기업 개요, 제품 포트폴리오, 주요 특징, 실적, 전략 등의 파라미터를 기준으로 정리하여 수록하였습니다.

주요 조사 대상 기업으로는 Fresenius Medical Care AG & Co.KGaA, Baxter, Angion Biomedica Corp, AM-Pharma, Quark Pharmaceuticals, Inc. 등이 있습니다.

이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.

세계 급성 신장 질환 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.

이해관계자들은 세계 급성 신장 질환 치료 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

목차

제1장 조사 목적과 전제조건

  • 조사 목적
  • 전제조건
  • 약어

제2장 시장 전망

  • 보고서 설명
    • 시장 정의와 범위
  • 주요 요약

제3장 시장 역학, 규제, 동향 분석

  • 시장 역학
  • 영향 분석
  • 규제 시나리오
  • 제품 발매/승인
  • PEST 분석
  • Porter's Five Forces 분석
  • 인수합병(M&A) 시나리오

제4장 세계의 급성 신손상(AKI) 치료 시장, 유형별, 2020-2032년(10억 달러)

  • 서론
  • Prerenal Acute Kidney Injury
  • Intrinsic Renal Acute Kidney Injury
  • Postrenal Acute Kidney Injury

제5장 세계의 급성 신손상(AKI) 치료 시장, 치료별, 2020-2032년(10억 달러)

  • 서론
  • 치료
  • 약제

제6장 세계의 급성 신손상(AKI) 치료 시장, 유통 채널별, 2020-2032년(10억 달러)

  • 서론
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제7장 세계의 급성 신손상(AKI) 치료 시장, 지역별, 2020-2032년(10억 달러)

  • 서론
  • 북미
  • 라틴아메리카
  • 유럽
  • 아시아태평양
  • 중동
  • 아프리카

제8장 경쟁 구도

  • Angion Biomedica Corp.
  • AM-Pharma
  • Quark Pharmaceuticals, Inc.
  • Baxter International, Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Braun Melsungen AG
  • Asahi Kasei Medical Co., Ltd.
  • LG Chem
  • Kringle Pharma, Inc.
  • AstraZeneca
  • Amgen Inc.
  • Gilead Sciences
  • Roche
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Novartis AG
  • AbbVie Inc.

제9장 애널리스트 추천 사항

  • 융성과 쇠퇴
  • Coherent Opportunity Map

제10장 참고 문헌과 조사 방법

  • 참고 문헌
  • 조사 방법
  • 출판사에 대해
LSH 25.04.02

Global Acute Kidney Injury Treatment Market is estimated to be valued at USD 1.96 Bn in 2025 and is expected to reach USD 3.43 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 1.96 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 8.30% 2032 Value Projection: USD 3.43 Bn
Figure. Acute Kidney Injury Treatment Market Share (%), By Region 2025
Acute Kidney Injury Treatment Market - IMG1

Acute kidney injury (AKI) refers to an abrupt loss of kidney function, resulting in the build-up of waste products in the blood that would normally be removed by the kidneys. It is a serious condition that requires prompt medical care to prevent further kidney damage and failure. Global acute kidney injury treatment market growth is driven by rising prevalence of comorbid conditions such as diabetes and hypertension that increases the risk of AKI. Furthermore, development of novel drugs and treatment approaches has expanded therapeutic options for patients. However, lack of awareness among people and healthcare providers about AKI can hamper the market growth.

Market Dynamics:

Global acute kidney injury treatment market growth is driven by rising geriatric population who are more susceptible to AKI due to age-related decline in kidney function. According to the United Nations, the number of people aged 65 years and above is projected to reach over 1.5 billion by 2050. Growing prevalence of chronic kidney diseases due to lifestyle changes can also drive the market growth. However, high costs associated with renal replacement therapies can limit widespread adoption. Lack of awareness about early diagnosis of AKI can hamper the market growth. Development of biomarkers for early detection of AKI presents lucrative opportunities for market players to expand their offerings in this area. Real-time monitoring of fluid status offers real-time customized care. Digital health solutions can also aid remote patient management.

Key features of the study:

This report provides in-depth analysis of the global acute kidney injury treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global acute kidney injury treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Fresenius Medical Care AG & Co. KGaA, Baxter, Angion Biomedica Corp, AM-Pharma, and Quark Pharmaceuticals, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global acute kidney injury treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute kidney injury treatment market

Detailed Segmentation-

  • Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Prerenal Acute Kidney Injury
    • Intrinsic Renal Acute Kidney Injury
    • Postrenal Acute Kidney Injury
  • Treatment Insights (Revenue, USD Bn, 2020 - 2032)
    • Therapy
    • Drugs
  • Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Angion Biomedica Corp.
    • AM-Pharma
    • Quark Pharmaceuticals, Inc.
    • Baxter International, Inc.
    • Fresenius Medical Care AG & Co. KGaA
    • Braun Melsungen AG
    • Asahi Kasei Medical Co., Ltd.
    • LG Chem
    • Kringle Pharma, Inc.
    • AstraZeneca
    • Amgen Inc.
    • Gilead Sciences
    • Roche
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Sanofi
    • Bristol-Myers Squibb
    • Eli Lilly and Company
    • Novartis AG
    • AbbVie Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Acute Kidney Injury Treatment Market, By Type
    • Global Acute Kidney Injury Treatment Market, By Treatment
    • Global Acute Kidney Injury Treatment Market, By Distribution Channel
    • Global Acute Kidney Injury Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Acute Kidney Injury Treatment Market, By Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Prerenal Acute Kidney Injury
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Intrinsic Renal Acute Kidney Injury
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Postrenal Acute Kidney Injury
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Acute Kidney Injury Treatment Market, By Treatment, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021- 2032
    • Segment Trends
  • Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Acute Kidney Injury Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Acute Kidney Injury Treatment Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Treatment, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

8. Competitive Landscape

  • Angion Biomedica Corp.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AM-Pharma
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Quark Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Baxter International, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Fresenius Medical Care AG & Co. KGaA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Braun Melsungen AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Asahi Kasei Medical Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • LG Chem
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Kringle Pharma, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Gilead Sciences
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Roche
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Novartis AG
  • AbbVie Inc.

9. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

10. References and Research Methodology

  • References
  • Research Methodology
  • About us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제